Syneos and CuraTeQ recruiting for Ph III clinical trial of BP11 (proposed omalizumab biosimilar)

Sep 22, 2021

Syneos Health and CuraTeQ Biologics (a subsidiary of Aurobindo) are recruiting participants for a comparative trial to be conducted in New Zealand to assess the pharmacokinetics, pharmacodynamics, safety and immunogenicity of 3 different products (BP11, US-Xolair and EU-Xolair) containing 150mg of omalizumab as subcutaneous injection in healthy male volunteers.  The estimated study completion date is October 2022.

Print Page Mail Article